There's a lot of discussion about risk/reward on this board.
I came across an interesting statistic.
Drugs which were granted priority review have an 80% chance of approval.
All other NDA drugs have about a 50% chance of approval.
Preclinicals and early stage drugs are long shots.
Of the drugs with PDUFA dates, Probuphine was granted priority review. So its odds of approval are in the 80% range. Then, if you factor in that Probuphine is an implant that is administering an already approved and safe drug (similar to dox in ThermoDox), the odds of approval increase to over 90%. It's as close to a sure thing as you can get in biotech.
So, after January, whatever happens here, you might want to check out TTNP. The PDUFA date is April 30th. There might be an ADCOM panel in late March.
If you are squeamish about the wild swings here or concerned about the risk/reward, TTNP could be the stock for you.
I'm not pumping, do your own DD.